Cannabidiol (Epidyolex®). HTA ID: 21024

Assessment Status Rapid Review complete
HTA ID 21024
Drug Cannabidiol
Brand Epidyolex®
Indication As adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older.
Assessment Process
Rapid review commissioned 09/06/2021
Rapid review completed 08/07/2021
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cannabidiol (Epidyolex®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.

The HSE has approved reimbursement following confidential price negotiations December 2021.